MOUNTAIN VIEW, Calif., Sept. 6, 2017 /PRNewswire/ -- AliveCor, the leader in FDA-cleared personal electrocardiogram (EKG) technology, today announced the results of four clinical research presentations that demonstrate that AliveCor's hyper-fast, 30 second, digital EKG can positively impact and potentially even save the lives of millions of people around the world who suffer from Atrial Fibrillation (AFib).

As a medtech leader, AliveCor uses advanced artificial intelligence, mobile, cloud, and micro-electrode technology to change the dynamic in cardiac care. AliveCor empowers patients worldwide to proactively manage heart health and provide the potential to vastly improve the quality of care in the fight against heart disease. AliveCor's Kardia Mobile enables patients and their care teams to easily, quickly, and inexpensively detect and manage possible AFib, the single leading cause of stroke and heart failure.

"Over 35 million people around the world unknowingly suffer from Atrial Fibrillation," said AliveCor CEO Vic Gundotra. "AFib is widely understood to be the leading predictor of stroke and heart failure. AliveCor's app based digital EKG enables patients to conveniently and precisely detect AFib and to deliver clinical grade EKGs to their health care providers."
Key Kardia Mobile-focused findings from the 2017 European Society of Cardiology Congress In Barcelona include:

Patients using Kardia Mobile had a 4X increase in AFib Detection: Professor Julian Halcox of Swansea University Hospital in Wales presented The REHEARSE-AF Study at ESC with simultaneous publication in Circulation, The Journal of the American Heart Association. This randomized study provided AliveCor Kardia units to 500 seniors, who used them to record two EKGs per week for a year and compared the results to 500 seniors who received conventional care from their General Practitioner. At the end of the year, the Kardia group had a 4-fold increase in AFib diagnosis compared to the control group, thereby enabling the initiation of potentially life-saving anticoagulant therapy.

Cleveland Clinic study shows Kardia Mobile AFib detection accuracy similar to that of physicians. Dr. Khaldoun Tarakji from the Cleveland Clinic presented the iREAD Study which evaluated the accuracy of the AliveCor automatic AFib algorithm versus expert cardiology over-read of both the Kardia recordings and 12-lead EKGs. Dr. Tarakji found that the Kardia algorithm in 52 patients had a 96.6% sensitivity and a 94% specificity compared to a cardiology over-read of the simultaneous 12-lead EKGs for the diagnosis of AFib. Additionally, over 93% of the patients found the Kardia to be easy to use and that it "lessened AFib-diagnosis anxiety."

Cardiology Homepage